Home » Stocks » EPZM

Epizyme, Inc. (EPZM)

Stock Price: $8.67 USD 0.12 (1.40%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 833.14M
Revenue (ttm) 22.04M
Net Income (ttm) -251.03M
Shares Out 101.79M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $8.67
Previous Close $8.55
Change ($) 0.12
Change (%) 1.40%
Day's Open 8.55
Day's Range 8.15 - 8.74
Day's Volume 1,262,271
52-Week Range 6.70 - 22.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that...

1 day ago - Business Wire

With the trading day about halfway over, markets pushed higher into the weekend. The Nasdaq was the biggest winner on the day, with the index up over 1.3%.

Other stocks mentioned: ETSY, MNST, NOK, FATE, IONS, NTLA
6 days ago - 24/7 Wall Street

Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.

6 days ago - Zacks Investment Research

Epizyme (EPZM) delivered earnings and revenue surprises of -23.21% and 7.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business an...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...

2 weeks ago - Business Wire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AFMD, CMRX, SEEL, WVE
1 month ago - 24/7 Wall Street

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today ...

2 months ago - Business Wire

Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it w...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Third subhead of release should read: Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 1b Portion of Phase 1b/2 Castration-Resistant Pr...

2 months ago - Business Wire

Epizyme (EPZM) delivered earnings and revenue surprises of -10.17% and 30.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Epizyme (NASDAQ:EPZM) rose 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 10.17% over the past year to ($0.65), which missed t...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business an...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...

2 months ago - Business Wire

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Participate in Jefferies Virtual London Healthcare Conference

6 months ago - Business Wire

Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

6 months ago - Zacks Investment Research

Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.

6 months ago - Benzinga

Epizyme (EPZM) delivered earnings and revenue surprises of 9.84% and -40.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business a...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the ...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...

6 months ago - Business Wire

Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.

8 months ago - Business Wire

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

9 months ago - Zacks Investment Research

Epizyme's (EPZM) CEO Rob Bazemore on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Reports Business Progress and Second Quarter 2020 Financial Results

9 months ago - Business Wire

Epizyme A Buy For Tazverik And Epigenetic Platform

10 months ago - Seeking Alpha

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: CLR, FOX, GRPN, AXS, CATM, ED, RPRX ...
10 months ago - Benzinga

The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.

10 months ago - Zacks Investment Research

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Shares of Epizyme Inc. EPZM, +4.81% were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory ...

10 months ago - Market Watch

The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.

10 months ago - The Motley Fool

If you have cash to spare, these cancer stocks are set to soar.

Other stocks mentioned: GTHX
10 months ago - The Motley Fool

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced

11 months ago - Seeking Alpha

Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.

1 year ago - Zacks Investment Research

Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

  Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.

1 year ago - Benzinga

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.

Other stocks mentioned: AIMT, ESPR, HZNP
1 year ago - The Motley Fool

About EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with... [Read more...]

Industry
Biotechnology
IPO Date
May 31, 2013
CEO
Robert Bazemore
Employees
304
Stock Exchange
NASDAQ
Ticker Symbol
EPZM
Full Company Profile

Financial Performance

In 2020, Epizyme's revenue was $15.76 million, a decrease of -33.77% compared to the previous year's $23.80 million. Losses were -$231.69 million, 36.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Epizyme stock is "Buy." The 12-month stock price forecast is 18.63, which is an increase of 114.88% from the latest price.

Price Target
$18.63
(114.88% upside)
Analyst Consensus: Buy